The Fundus Structural and Functional Predictions of DME Patients After Anti-VEGF Treatments

Hang Xie1†, Shihao Huang1†, Qingliang Liu2†, Yifan Xiang3, Fabao Xu4, Xiaoyan Li4 and Chun-Hung Chiu1*

1 Business School, Sun Yat-Sen University, Guangzhou, China, 2 School of Computer Science and Engineering, Sun Yat-Sen University, Guangzhou, China, 3 State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou, China, 4 Department of Ophthalmology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China

Diabetic retinopathy (DR) is an important complication with a high incidence of 34.6% in the diabetic populations. DR could finally lead to vision impairment without effective interventions, during which, diabetic macular edema (DME) is a key phase causing visual loss. Up to date, antivasculeral endothelial growth factor (anti-VEGF) therapy is the first-line treatment for DME which has achieved relatively better clinical outcomes than traditional treatments. However, there are several kinds of anti-VEGF medicines, and patients are sensitive to different anti-VEGF treatments. In addition, its effectiveness is unstable. Considering the patients’ need to accept continual anti-VEGF treatments and its price is comparatively high, it is clinically important to predict the prognosis after different anti-VEGF treatments. In our research, we used the demographic and clinical data of 254 DME patients and 2,763 optical coherence tomography (OCT) images from three countries to predict the fundus structural and functional parameters and treatment plan in 6 months after different anti-VEGF treatments. Eight baseline features combined with 11 models were applied to conduct seven prediction tasks. Accuracy (ACC), the area under curve (AUC), mean absolute error (MAE), and mean square error (MSE) were respectively used to evaluate the classification and regression tasks. The ACC and AUC of structural predictions of retinal pigment epithelial detachment were close to 1.000. The MAE and MSE of visual acuity predictions were nearly 0.3 to 0.4 logMAR. The ACC of treatment plan regarding continuous injection was approaching 70%. Our research has achieved great performance in the predictions of fundus structural and functional parameters as well as treatment plan, which can help ophthalmologists improve the treatment compliance of DME patients.

Keywords: diabetic macular edema, optical coherence tomography, visual acuity, clinical effectiveness, prognosis prediction
INTRODUCTION

Diabetes is a global public health issue (1). According to published results, in 11 adults had diabetes worldwide in 2015, and the diabetic population will increase to 642 million by 2040 (2–4). Diabetic retinopathy (DR) is an important complication with a high incidence of 24.7% to 37.5% in the diabetic populations (5). DR could gradually progress and finally lead to vision impairment without effective intervention, during which diabetic macular edema (DME) is a key phase causing visual loss. The morbidity of DME is 3.1% to 7.9% in the diabetic populations, and most of them need prompt and effective treatment to avoid severe visual impairment (6).

Up to date, antivascular endothelial growth factor (anti-VEGF) therapy is the first-line treatment for DME and has achieved relatively better clinical outcomes than traditional treatments of retinal photocoagulation and surgery (7–9). There are several kinds of anti-VEGF medicines, involving bevacizumab, ranibizumab, aflibercept, and so on. However, patients are sensitive to different anti-VEGF treatments and its effectiveness is unstable (10–12). Considering that patients need to accept repetitive anti-VEGF treatments and its price is comparatively high, it is clinically important to predict the prognosis after different anti-VEGF treatments (13, 14).

In our study, we established intelligent models for fundus structural and functional predictions of DME patients after different anti-VEGF treatments. Based on the multinational data, we applied several algorithms to predict the functional parameter of visual acuity (VA), structural parameters of central retinal thickness (CRT) and other four parameters, and clinical advice of continuing injection (CI) 6 months in advance. Our models have achieved great performance in different prediction tasks, which can help ophthalmologists make treatment plans for DME patients and provide research basis for other retinopathies.

MATERIALS AND METHODS

The data were downloaded from the open dataset provided by the Asia Pacific Tele-Ophthalmology Society (APTOS) and the Department of Ophthalmology, Qilu Hospital, Shandong University, from October 2018 to May 2021. The APTOS data were applied to train and test the models. The Qilu data were applied for external validation. Our ethics committee ruled that written informed consent was not required because our study was retrospective in nature and all the images were fully anonymized. Moreover, this study adhered to the tenets of the Declaration of Helsinki (2020KYPJ024).

DATA COLLECTION

The APTOS data were obtained from the Rajavithi Hospital of Thailand and the Aravind Eye Hospital of India, then labeled by the Zhongshan Ophthalmic Center of China. The Qilu data were extracted from the clinical records. Only patients diagnosed with DME and accepting anti-VEGF treatments are enrolled. The inclusion criteria were as follows: (1) aged greater or equal to 18 years; (2) diagnosed with DME; and (3) accepting consecutive monthly anti-VEGF therapy of bevacizumab, aflibercept, conbercept, ranibizumab, or combination for 6 months. The exclusion criteria were as follows: (1) presence of any other retinal diseases including age-related macular degeneration (AMD), retinal vein occlusion (RVO), polypoidal choroidal vasculopathy (PCV), and so on; (2) low image quality caused by media opacities; or (3) an abnormal signal strength index of images. The follow-up points were at 6 months after anti-VEGF therapy.

The demographic information of age and gender were recorded. Pretherapeutic visual acuity (pre-VA) and visual acuity (VA) after anti-VEGF therapy for 6 months were tested. Based on the optical coherence tomography (OCT) of patients before and after anti-VEGF therapy, five imaging characteristics of central retinal thickness (CRT), and presence of retinal interlayer fluid (RIF), subretinal pigment epithelium fluid (SRF), retinal pigment epithelial detachment (PED), and retinal hyperreflexia (RHF) were measured and recorded by ophthalmologists with clinical work experience of more than 5 years. The clinical decision label of suggesting continuous injection (CI) of anti-VEGF medicine was made based on its therapeutic effect after 6 months according to changes of VA and imaging characteristics, which was labeled by professors with clinical work experience of more than 10 years. As the appearance and treatment of binocular DME are usually asynchronous, we treated each eye as a separate case in data collection.

MODEL TRAINING AND EVALUATION

The research procedure is shown in Figure 1. Eight parameters were applied to train the prediction models, including age, gender, pre-VA, pre-CRT, pre-RIF, pre-SRF, pre-PED, and pre-RHF at baseline. Five classification prediction models were constructed to predict the CI and the presence of RIF, SRF, PED, and RHF. Six regression prediction models were established to predict VA and CRT 6 months in advance.

The classification prediction models included classical random forest (RF), generalized regression neural network (GRNN), probabilistic neural network (PNN), extreme learning machine (ELM), and support vector machine (SVM) modeling. Also, their classification performances were evaluated by classification accuracy (ACC) and area under the curve (AUC). ACC is defined as the proportion of the sum of true-positive samples (TP) and the true-negative samples (TN) to the total number of samples (N) to be predicted, as follows,

\[
ACC = \frac{TP + TN}{N}.
\]

AUC represents the area under the ROC curve, and AUC takes values between 0 and 1, where a larger AUC indicates a better model performance.
The regression prediction models contained RF, ordinary least squares (OLS), back propagation (BP) network, ELM, radial basis function (RBF) network, and support vector regression (SVR) modeling. The prediction performances of regression models were quantified with the mean absolute error (MAE) and root mean square error (RMSE). The MAE is defined as the average value of the absolute error of the prediction results, which directly reflects the deviation of the predicted values from the actual values, as follows,

$$
\text{MAE} = \frac{1}{N} \sum_{i=1}^{N} |\tilde{y}_i - y_i|,
$$

where $\tilde{y}_i$ and $y_i$ represent the model prediction value and the real value for the $i$th sample, respectively. The RMSE is the square root of mean square error (MSE), which is calculated as the average value of the square of the error of the prediction results, as follows,

$$
\text{RMSE} = \sqrt{\frac{1}{N} \sum_{i=1}^{N} (\tilde{y}_i - y_i)^2}.
$$

RESULTS

Of 216 patients, 335 eyes were included from APTOS data and 38 eyes of 38 patients were enrolled form Qilu data (Table 1).
The DME patients were aged 26 to 84 years old with a mean age of nearly 56 years old. One hundred fourteen (34.0%) patients and 22 (57.9%) patients were men in the APTOS and Qilu data, respectively. The pre-VAs were 0.74 ± 0.60 (0–3) logMAR and 1.20 ± 0.63 (0–3) logMAR in two datasets (p < 0.001). The pre-CRTs ranged from 151 to 1,345 μm with mean values of 426.71 ± 177.88, 415.21 ± 131.98, and 699.87 ± 921.63 μm in the training, test, and external validation groups, respectively. The statistical differences of all characteristics before and after treatments between the APTOS and Qilu data are shown in Table 1. Except for the baseline age, pre-VA and pre-RHF, there was no statistical difference between two datasets. DME patients of three groups showed VA improvement, CRT decrease, and percentage changes of RIF, SRF, PED, and RHF, which are described in detail in Table 1.

Five structural prediction models obtained ACCs and AUCs at different levels, of which the RF and SVM models achieved best performances (Table 2). In the internal test, ACCs of presence predictions regarding RIF, SRF, PED, and RHF were 0.902, 0.825, 0.937, and 0.939 with the RF model and 0.912, 0.787, 0.965, and 0.948 with the SVM model. AUCs of presence predictions regarding RIF, SRF, PED, and RHF were 0.844, 0.645, 0.772, and 0.891 with the RF model and 0.865, 0.525, 0.906, and 0.890 with the SVM model. In the external validation, these two models also obtained high-level accuracies that ACCs of presence predictions regarding RIF, SRF, PED, and RHF were 0.858, 0.783, 1.000, and 0.917 with the RF model and 0.868, 0.777, 1.000, and 0.895 with the SVM model. ACCs of presence predictions regarding RIF, SRF, PED, and RHF were 0.782, 0.654, 1.000, and 0.944 with the RF model and 0.812, 0.622, 1.000, and 0.911 with the SVM model, which have achieved excellent performance in the PED predictions with an ACC of 1.000 in external validation. The predictions of RIF and RHF obtained high accuracies of more than 0.900 as well. In the clinical suggestions of CI predictions, the accuracy is close to 0.700. In the internal test, the ACCs of CI predictions were 0.671 with the RF model and 0.697 with the SVM model. The AUCs were 0.607 with the RF model and 0.634 with the SVM model. In the external validation, ACCs were 0.674 and 0.656 and AUCs were 0.649 and 0.671 respectively in the RF and SVM models.

The SVR and RF models obtained the best performances in VA and CRT predictions (Table 2). MAEs of VA predictions were 0.262 and 0.302 logMAR in internal tests and 0.387 and 0.485 logMAR in external validations. Prediction errors were equivalent to nearly three lines of visual chart. Predictions errors of CRT were exhibited in Table 2. Prediction errors of MAE and RMSE were close to 100 to 150 μm.

Feature weights of CI and VA predictions of the best two models are indicated in Figure 2. Two models showed different weight patterns in the same tasks. In the CI predictions, the most important features were pre-RIF (0.345), pre-PED (0.236), and pre-RHF (0.419) according to the SVM model. However, in the RF model, the most important features were pre-VA (0.257), pre-CRT (0.366), and pre-RHF (0.175). In the VA predictions, the pre-VA had the highest weights of 0.826 and 0.319 in the SVR and RF models, respectively. The pre-CRT (0.321) also played an important role in VA predictions based on the RF model.

**DISCUSSION**

Our study established classification and prediction models with multinational data to predict the treatment effects of anti-VEGF therapy for DME patients. The models have achieved excellent performance in prediction tasks of structural and functional parameters as well as clinical suggestions 6 months in advance, which can help ophthalmologists with DME patients.

---

**TABLE 1** The characteristics of patients according to groups.

| Characteristics | Training group | Test group | External validation | p-values |
|-----------------|----------------|------------|---------------------|----------|
| Patients        | 182            | 34         | 38                  |          |
| Gender (men)    | 98 (53.85%)    | 16 (47.06%)| 22 (57.89%)         | 0.726    |
| Eyes            | 56.55 ± 9.98   | 57.59 ± 10.27| 61.84 ± 11.19      | 0.005    |
| Age (years)     | 301            | 34         | 38                  |          |
| Pre-VA (logMAR) | 0.74 ± 0.60    | 0.60 ± 0.42| 1.20 ± 0.63         | <0.001   |
| Pre-CRT (μm)    | 426.71 ± 177.88| 415.21 ± 131.98| 699.87 ± 921.63    | 0.08     |
| Pre-RIF         | 243 (80.73%)   | 27 (79.41%)| 34 (89.47%)         | 0.355    |
| Pre-SRF         | 98 (32.56%)    | 10 (29.41%)| 18 (47.37%)         | 0.260    |
| Pre-PED         | 26 (8.64%)     | 1 (2.94%)  | 2 (5.26%)           | 0.609    |
| Pre-RHF         | 205 (68.11%)   | 20 (58.82%)| 20 (52.63%)         | 0.039    |
| Posttreatment   |                |            |                     |          |
| VA (logMAR)     | 0.69 ± 0.59    | 0.52 ± 0.31| 0.87 ± 0.64         | 0.184    |
| CRT (μm)        | 391.08 ± 157.26| 392.56 ± 140.09| 355.55 ± 132.69    | 0.243    |
| RIF             | 242 (80.40%)   | 25 (73.53%)| 29 (76.32%)         | 0.359    |
| SRF             | 66 (21.93%)    | 4 (11.76%) | 8 (21.05%)          | 0.676    |
| PED             | 26 (8.64%)     | 1 (2.94%)  | 2 (5.26%)           | 0.638    |
| RHF             | 202 (67.11%)   | 19 (55.88%)| 20 (52.63%)         | 0.056    |
| CI              | 203 (67.44%)   | 25 (73.53%)| 21 (55.26%)         | 0.052    |

*p-values showed the statistical differences of characteristics between the APTOS and Qilu data.*

VA, visual acuity; CRT, central retinal thickness; RIF, retinal interlayer fluid; SRF, subretinal pigment epithelium fluid; PED, retinal pigment epithelial detachment; RHF, retinal hyperreflexia; CI, continuous injection.
DME is an important stage of RD, which needs timely treatment, otherwise may cause severe visual impairment (15). Anti-VEGF treatment is the first-line treatment of DME (16, 17). Increasing researches were conducted to explore the clinical effect and limitation of anti-VEGF treatment (11, 18–21). Although anti-VEGF treatment was proved to function better than previous therapies of laser therapy and steroid therapy, it had some limitations as well (22–24). Patients need long-term and consecutive anti-VEGF injections, and the complication morbidity will increase with the treatment progress (7, 25, 26). The potential ocular complications include entophthalmia, glaucoma, and retinal detachment, which can lead to a more severe visual loss (27, 28). Consequently, to predict the therapeutic effect of anti-VEGF treatment can provide basis to make intervention plan for both ophthalmologists and patients. The functional prediction of VA and treatment plan prediction of CI both serve as key roles in treatment guidance. The prediction of CI is an impossible task for human ophthalmologists, even for experienced fundus professors. Our models achieved nearly 70% accuracy in the CI predictions, which provided a new sight in the understanding treatment effectiveness.

In our research, we finished the structural prediction tasks of five parameters, including CRT, RIF, SRF, PED, and RHF, which are all relatively important in the DME process and prognosis (29). Thick CRT and the presence of RIF, SRF, PED, and RHF all indicate there are still effusion and exudation in the lesion areas and that the prognosis is unsatisfactory (12, 30, 31). Previous studies have published relative prediction results, and some studies accurately predicted the VA and CRT of DME patients after anti-VEGF treatment by clinical information and OCT data (32–35). Honghua Yu and his team have published results predicting the VA and CRT of DME patients 1 month after anti-VEGF treatments (36). Our research has achieved earlier predictions of 6 months with more parameters. Our models obtained high accuracies in the presence predictions of more structural parameters, including RIF, SRF, PED, and RHF, especially the presence of PED, which provided more information about the treatment effects. Moreover, some other retinopathies, such as central serous chorioretinopathy and age-related macular degeneration, have similar pathological changes.
VEGF treatment. May provide a new idea for studied on the effectiveness of anti-
support the continuous injection of anti-VEGF medicine, which may obtain higher clinical effectiveness with CI. The presence of these structural lesions indicates there are chronic vascular leakage and fluid accumulation, which may cause angiogenesis. As a result, anti-VEGF treatment is beneficial to patients with these structural lesions. Our study found the clinical basis to support the continuous injection of anti-VEGF medicine, which may provide a new idea for studied on the effectiveness of anti-VEGF treatment.

LIMITATION
Some limitations of our research should be considered. Larger samples of DME patients are needed to enrich the data and to improve the prediction accuracy. Moreover, data form more external validations are necessary to test the stability of prediction models. Additionally, the intelligent models for predicting the effect of different anti-VEGF treatments are essential to assist doctors in making a clinical plan.

DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

REFERENCES
1. Zimmet PZ. Diabetes and Its Drivers: The Largest Epidemic in Human History. Clin Diabetes Endocrinol (2017) 3:1. doi: 10.1186/s40842-016-0039-3
2. Bellary S, Kyrou I, Brown JE, Bailey CJ. Type 2 Diabetes Mellitus in Older Adults: Clinical Considerations and Management. Nat Rev Endocrinol (2021) 17:534–48. doi: 10.1038/s41574-021-00512-2
3. Zheng Y, Ley SH, Hu FB. Global Aetiology and Epidemiology of Type 2 Diabetes Mellitus and Its Complications. Nat Rev Endocrinol (2018) 14:88–98. doi: 10.1038/s41570-017-151
4. Holman N, Young B, Gadsby R. Current Prevalence of Type 1 and Type 2 Diabetes in Adults and Children in the UK. Diabetes Med (2015) 32:1119–20. doi: 10.1111/dme.12791
5. Flaxel CJ, Adelman RA, Bailey ST, Fawzi A, Lim JI, Vemulakonda GA, et al. Diabetic Retinopathy Preferred Practice Pattern®. Ophthalmology (2020) 127: P66–66P145. doi: 10.1016/j.ophtha.2019.09.025
6. Wang FH, Liang YB, Zhang F, Wang JJ, Wei WB, Tao QS, et al. Prevalence of Diabetic Retinopathy in Rural China: The Handan Eye Study. Ophthalmology (2009) 116:461–7. doi: 10.1016/j.ophtha.2008.10.003
7. Malhotra NA, Greenlee TE, Iyer AI, Conti TF, Chen AX, Singh RP, Racial, Ethnic, and Insurance-Based Disparities Upon Initiation of Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema in the US. Ophthalmology (2021) 128:1438–47. doi: 10.1016/j.ophtha.2021.03.010
8. Bressler SB, Oda I, Maguire MG, Dhoot DS, Glassman AR, Jampol LM, et al. Factors Associated With Visual Acuity and Central Subfield Thickness Changes When Treating Diabetic Macular Edema With Anti-Vascular Endothelial Growth Factor Therapy: An Exploratory Analysis of the Protocol T Randomized Clinical Trial. JAMA Ophthalmol (2019) 137:382–9. doi: 10.1001/jamaophthalmol.2018.6786
9. Brown DM, Ou WC, Wong TP, Kim CY, Croft DE, Wykoff CC. Targeted Retinal Photocoagulation for Diabetic Macular Edema With Peripheral Retinal Nonperfusion: Three-Year Randomized DAVE Trial. Ophthalmology (2018) 125:68–90. doi: 10.1016/j.jophtha.2017.11.026
10. Bhandari S, Nguyen V, Fraser-Bell S, Mehta H, Viola F, Baudin F, et al. Ranibizumab or Aflibercept for Diabetic Macular Edema: Comparison of 1-Year Outcomes From the Fight Retinal Blindness! Registry. Ophthalmology (2020) 127:608–15. doi: 10.1016/j.jophtha.2019.11.018
11. Glassman AR, Wells JA, Xio J, Maguire MG, Antoszyk AN, Baker C, et al. Five-Year Outcomes After Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study). Ophthalmology (2020) 127:1201–10. doi: 10.1016/j.jophtha.2020.03.021
12. Bressler NM, Beaulieu WT, Glassman AR, Blinder KJ, Bressler SB, Jampol LM, et al. Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial. JAMA Ophthalmol (2018) 136:257–69. doi: 10.1001/jamaophthalmol.2017.6565
13. Wells JA, Glassman AR, Jampol LM, Aiello LP, Antoszyk AN, Baker CW, et al. Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema. JAMA Ophthalmol (2016) 134:127–34. doi: 10.1001/jamaophthalmol.2015.4599
14. Reddy RK, Pieramici DJ, Gune S, Ghanekar A, Lu N, Quezada-Ruiz C, et al. Efficacy of Ranibizumab in Eyes With Diabetic Macular Edema and Macular

ETHICS STATEMENT
Our ethics committee ruled that written informed consent was not required because our study was retrospective in nature and all the images were fully anonymized. Moreover, this study adhered to the tenets of the Declaration of Helsinki (2020KYPJ024). The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS
HX, SH, and C-HC conceived and designed the experiments. FX and XL collected the data. YX, FX, and XL labeled the data. SH and QL performed the experiments and analyzed the data. HX wrote the paper, and SH and CHC revised it. All authors read and approved the final manuscript.

FUNDING
This study was funded by the National Natural Science Foundation of China (Grant No. 71971224 and 71721001) and Guangdong Basic and Applied Basic Research Foundation (Grant No. 2020A1515011081). The sponsors of the study played no role in the study protocol design; data collection, analysis, or interpretation; manuscript preparation; or the decision to submit the manuscript for publication.

ACKNOWLEDGMENTS
The authors are grateful to the open APTOS data and all DME patients for supporting our study.
Nonperfusion in RIDE and RISE. *Ophthalmology* (2018) 125:1568–74. doi: 10.1016/j.ophtha.2018.04.002

15. Bandeira F, Battaglia Pantaleoni M, Lanzetta P, Loewenstein A, Massin P, Menchini F, et al. Diabetic Macular Edema. *Dev Ophthalmol* (2017) 58:102–38. doi: 10.1159/000455277

16. Kim Ej, Lin VW, Rodriguez SM, Chen A, Loya A, Weng CY. Treatment of Diabetic Macular Edema. *Curr Diabetes Rep* (2019) 19:68. doi: 10.1007/s11892-019-1188-4

17. Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, Berg K, Chakravarty U, Gerendas BS, et al. Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA). *Ophthalmologica* (2017) 237:185–222. doi: 10.1159/000458539

18. Arima M, Nakao S, Yamaguchi M, Feng H, Fujiy I, Shibata K, et al. Claudin-5 Redistribution Induced by Inflammation Leads to Anti-VEGF-Resistant Diabetic Macular Edema. *Diabetes* (2020) 69:981–99. doi: 10.2337/db19-1121

19. Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, et al. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results From a Comparative Effectiveness Randomized Clinical Trial. *Ophthalmology* (2016) 123:1351–9. doi: 10.1016/j.ophtha.2016.02.022

20. Banaee T, Ashraf M, Conti FF, Singh RP. Switching Anti-VEGF Drugs in the Treatment of Diabetic Macular Edema. *Ophthalmic Surg Lasers Imaging Retina* (2017) 48:748–54. doi: 10.3928/23258160-20170829-10

21. Virgili G, Parravano M, Evans JR, Gordon I, Lucenteforte E. Anti-Vascular Endothelial Growth Factor for Diabetic Macular Oedema: A Network Meta-Analysis. *Cochrane Database Syst Rev* (2017) 6:CD007419. doi: 10.1002/14651858.CD007419.pub5

22. Sun JK. Intravitreal Anti-VEGF Therapy With Prompt or Deferred Laser Compared With Steroid With Prompt Laser and Prompt Laser Alone for Treatment of Diabetic Macular Edema. *Curr Diabetes Rep* (2011) 11:227–9. doi: 10.1007/s11892-011-0201-3

23. Hussain RM, Ciulla TA. Treatment Strategies for Refractory Diabetic Macular Edema: Switching Anti-VEGF Treatments, Adopting Corticosteroid-Based Treatments, and Combination Therapy. *Expert Opin Biol Ther* (2016) 16:365–74. doi: 10.1517/14712598.2016.1131265

24. Mansour SE, Browning DJ, Wong K, Flynn HW Jr, Bhavsar AR. The Evolving Treatment of Diabetic Retinopathy. *Clin Ophthalmol* (2020) 14:653–78. doi: 10.2147/OPHTH.S23637

25. Chang CK, Cheng CK, Peng CH. The Incidence and Risk Factors for the Development of Vitreomacular Interface Abnormality in Diabetic Macular Edema Treated With Intravitreal Injection of Anti-VEGF. *Eye (Lond)* (2017) 31:762–70. doi: 10.1038/eye.2016.317

26. Gabrielle PH, Massin P, Arnould L, Couturier A, Bouché-Pillon J, Maupin E, et al. Development of a 1-Year Risk-Prediction Nomogram for Good Functional Response With Anti-VEGF Agents in Naïve Diabetic Macular Oedema. *Acta Ophthalmol* (2020) 98:e975–82. doi: 10.1111/aos.14428

27. Durand ML. Endophthalmitis. *Clin Microbiol Infect* (2013) 19:227–34. doi: 10.1111/1469-0691.12118

28. Cox JT, Elliott D, Sobotin L. Inflammatory Complications of Intravitreal Anti-VEGF Injections. *J Clin Med* (2021) 10:981–96. doi: 10.3390/jcm10060981

29. Lally DR, Shah CP, Heier JS. Vascular Endothelial Growth Factor and Diabetic Macular Edema. *Surv Ophthalmol* (2016) 61:759–68. doi: 10.1016/j.survophthal.2016.03.010

30. Wong TY, Cheung CM, Larsen M, Sharma S, Simó R. Diabetic Retinopathy. *Nat Rev Dis Primers* (2016) 2:16012. doi: 10.1038/nrdp.2016.12

31. Sun JK, Lin MM, Lammer J, Prager S, Sarangi R, Silva PS, et al. Disorganization of the Retinal Inner Layers as a Predictor of Visual Acuity in Eyes With Center-Involved Diabetic Macular Edema. *JAMA Ophthalmol* (2014) 132:1309–16. doi: 10.1001/jamaophthalmol.2014.2350

32. Chakraborty S, Gupta M, Deviakshamani CS, Patel K, Ankit C, Ganesh Babu TC, et al. Narrative Review of Artificial Intelligence in Diabetic Macular Edema: Diagnosis and Predicting Treatment Response Using Optical Coherence Tomography. *Indian J Ophthalmol* (2021) 69:2999–3008. doi: 10.4103/ijo.IJO_1482_21

33. Gunasekaran DV, Ting D, Tan G, Wong TY. Artificial Intelligence for Diabetic Retinopathy Screening, Prediction and Management. *Curr Opin Ophthalmol* (2020) 31:357–65. doi: 10.1097/ICU.0000000000000693

34. Gallardo M, Munk MR, Kurmann T, De Zanet S, Mosinska A, Karagoz IK, et al. Machine Learning Can Predict Anti-VEGF Treatment Demand in a Treat-And-Extend Regimen for Patients With Neovascular AMD, DME, and RVO Associated Macular Edema. *Ophthalmol Retina* (2021) 5:604–24. doi: 10.1016/j.orl.2021.05.002

35. Cao J, You K, Jin K, Lou L, Wang Y, Chen M, et al. Prediction of Response to Anti-Vascular Endothelial Growth Factor Treatment in Diabetic Macular Oedema Using an Optical Coherence Tomography-Based Machine Learning Method. *Acta Ophthalmol* (2021) 99:e19–e26. doi: 10.1111/aos.14514

36. Liu B, Zhang B, Hu Y, Cao D, Yang D, Wu Q, et al. Automatic Prediction of Treatment Outcomes in Patients With Diabetic Macular Edema Using Ensemble Machine Learning. *Ann Transl Med* (2021) 9:43. doi: 10.21037/atm-20-1431

37. Kaye R, Chandra S, Seth J, Boon C, Sivaprasad S, Lotery A. Central Serous Chorioretinopathy: An Update on Risk Factors, Pathophysiology and Imaging Modalities. *Prog Retin Eye Res* (2020) 79:100865. doi: 10.1016/j.preteyeres.2020.100865

38. van Lookeren Campagne M, LeCouter J, Yasanp BL, Ye W. Mechanisms of Age-Related Macular Degeneration and Therapeutic Opportunities. *J Pathol* (2014) 234:151–64. doi: 10.1002/path.4266

39. Ding X, Patel M, Chan CC. Molecular Pathology of Age-Related Macular Degeneration. *Prog Retin Eye Res* (2009) 28:1–18. doi: 10.1016/j.preteyeres.2008.10.001

40. Romero-Aroca P, Baiget-Bernaldiz M, Pareja-Rios A, Lopez-Galvez M, Navarro-Gil R, Verges R. Diabetic Macular Edema Pathophysiology. *Vasogenic Versus Inflammatory. J Diabetes Res* (2016) 2016:2156273. doi: 10.1155/2016/2156273

41. Gandorfer A. Diffuse Diabetic Macular Edema: Pathology and Implications for Surgery. *Dev Ophthalmol* (2007) 39:88–95. doi: 10.1159/000098501

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Xie, Huang, Liu, Xiang, Xu, Li and Chiu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.